Molecular Partners Ag Quick Ratio (MOLN) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Molecular Partners Ag  (NASDAQ: MOLN)

Molecular Partners Ag's Quick Ratio

MOLN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Molecular Partners Ag's Cash & cash equivalent, this led to improvement in Molecular Partners Ag's Quick Ratio to 9.44, above Molecular Partners Ag average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Quick Ratio than Molecular Partners Ag in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 424.

Explain Quick Ratio?
How much Cash & cash equivalents MOLN´s has?
What are MOLN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MOLN Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 2.24 % 16.83 % 2.24 % 16.83 % -25.19 %
Y / Y Cash & cash equivalent Change 47.86 % 47.86 % 44.95 % 47.86 % -12.04 %
Quick Ratio MRQ 9.44 7.5 9.37 7.5 6.53
MOLN's Total Ranking # 424 # 0 # # #
Seq. Current Liabilities Change -20.64 % 26.01 % -20.64 % 28.84 % -9.32 %
Seq. Cash & cash equivalent Change -0 % 0.85 % -0.85 % 47.86 % -0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 194
Overall Market # 424


Quick Ratio Statistics
High Average Low
7.5 4.94 1.53
(Dec 31 2025)   (Dec 31 2021)




Financial Statements
Molecular Partners Ag's Current Liabilities $ 11 Millions Visit MOLN's Balance sheet
Molecular Partners Ag's Cash & cash equivalent $ 104 Millions Visit MOLN's Balance sheet
Source of MOLN's Sales Visit MOLN's Sales by Geography


Cumulative Molecular Partners Ag's Quick Ratio

MOLN's Quick Ratio for the trailling 12 Months

MOLN Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 9.89 % 1.25 % -12.25 % -18.17 % -28.16 %
Y / Y Cash & cash equivalent TTM Growth 47.12 % 30.73 % 15.39 % 6.16 % -8.13 %
Quick Ratio TTM 8.34 7.7 7.32 6.68 6.23
Total Ranking TTM # 4080 # 0 # # #
Seq. Current Liabilities TTM Growth 0.49 % 4.2 % 0.51 % 4.41 % -7.41 %
Seq. Cash & cash equivalent TTM Growth 8.82 % 9.68 % 10.13 % 11.93 % -3.3 %

Quick ratio ranking by company, industry and sector >> Back to MOLN Financial Strength Comparisons >> Go to Compare MOLN Quick Ratio to its Competitors

On the trailing twelve months basis MOLN Cash & cash equivalent soared by 47.86 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Molecular Partners Ag's Quick Ratio to 8.34, above MOLN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 152 other companies have achieved higher Quick Ratio than Molecular Partners Ag. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4080.

Explain Quick Ratio?
How much Cash & cash equivalents MOLN´s has?
What are MOLN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 153
Healthcare Sector # 941
Within the Market # 4080


trailing twelve months Quick Ratio Statistics
High Average Low
7.93 4.97 1.53
(Dec 31 2025)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Cg Oncology Inc   24.07 $ 742.155  Millions$ 30.836  Millions
Protara Therapeutics Inc  20.72 $ 200.909  Millions$ 9.697  Millions
Leonabio Inc   18.50 $ 176.631  Millions$ 9.550  Millions
Hemab Therapeutics Holdings Inc   18.49 $ 185.485  Millions$ 10.030  Millions
Vor Biopharma Inc   18.29 $ 455.208  Millions$ 24.891  Millions
Kyverna Therapeutics Inc   18.26 $ 279.253  Millions$ 15.296  Millions
Kymera Therapeutics Inc   18.23 $ 848.276  Millions$ 46.531  Millions
Maze Therapeutics Inc   15.16 $ 341.917  Millions$ 22.556  Millions
Compass Therapeutics Inc   14.96 $ 208.906  Millions$ 13.968  Millions
Candel Therapeutics Inc   14.00 $ 119.731  Millions$ 8.552  Millions
In8bio Inc   13.95 $ 27.092  Millions$ 1.942  Millions
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Crispr Therapeutics Ag  13.25 $ 1,975.828  Millions$ 149.120  Millions
Tscan Therapeutics Inc   13.22 $ 152.406  Millions$ 11.528  Millions
Eikon Therapeutics Inc   13.15 $ 335.975  Millions$ 25.549  Millions
Precision Biosciences Inc  12.97 $ 115.585  Millions$ 8.913  Millions
Beam Therapeutics Inc   12.85 $ 1,245.210  Millions$ 96.935  Millions
Anavex Life Sciences Corp   12.60 $ 102.577  Millions$ 8.141  Millions
Vaxcyte Inc   12.49 $ 1,560.959  Millions$ 124.972  Millions
Kalaris Therapeutics Inc   12.15 $ 117.982  Millions$ 9.714  Millions
Imagenebio Inc   12.05 $ 135.349  Millions$ 11.234  Millions
Taysha Gene Therapies Inc   12.04 $ 319.767  Millions$ 26.552  Millions
Immunovant Inc   10.40 $ 713.971  Millions$ 68.677  Millions
Cullinan Therapeutics Inc   10.22 $ 377.896  Millions$ 36.961  Millions
X4 Pharmaceuticals Inc  9.82 $ 252.998  Millions$ 25.757  Millions
Molecular Partners Ag  9.44 $ 104.149  Millions$ 11.027  Millions
4d Molecular Therapeutics Inc   9.15 $ 402.655  Millions$ 43.985  Millions
Prokidney Corp   9.10 $ 270.017  Millions$ 29.671  Millions
Sab Biotherapeutics Inc   9.04 $ 96.592  Millions$ 10.681  Millions
Denali Therapeutics Inc   8.82 $ 867.879  Millions$ 98.351  Millions

Date modified: 2026-09-09T12:37:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.